Synthesized V7 QRS Amplitude and Oversensing Episodes in Patients With Subcutaneous Implantable Cardioverter-Defibrillators

被引:0
|
作者
Okajima, Takashi [1 ,2 ]
Ishikawa, Shinji [1 ]
Yanagisawa, Satoshi [2 ,3 ]
Okamoto, Takayuki [1 ]
Uemura, Yusuke [1 ]
Takemoto, Kenji [1 ]
Inden, Yasuya [2 ]
Murohara, Toyoaki [2 ]
Watarai, Masato [1 ]
机构
[1] Anjo Kosei Hosp, Dept Cardiol, Anjo, Japan
[2] Nagoya Univ, Dept Cardiol, Grad Sch Med, Nagoya, Japan
[3] Nagoya Univ, Dept Adv Cardiovasc Therapeut, Grad Sch Med, Nagoya, Japan
来源
关键词
inappropriate shock therapies; oversensing episodes; QRS amplitude; subcutaneous implantable cardioverter-defibrillator; synthesized 18-lead electrocardiogram; EFFICACY; SAFETY; ORIGIN;
D O I
10.1111/pace.15086
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundPatients with subcutaneous implantable cardioverter-defibrillators (S-ICDs) experience an oversensing episode (OS) more frequently than those with transvenous ICDs. However, no established electrocardiography (ECG) parameters can accurately detect an OS. This study aimed to evaluate the incidence of an OS in real-world clinical practice and the association of synthesized 18-lead ECG (syn18-ECG) parameters with an OS. MethodsWe retrospectively included 21 consecutive patients who underwent S-ICD implantation and collected syn18-ECG parameters. We placed the generator in a deep posterior position and defined an OS as an inappropriate charging episode caused by cardiac or noncardiac signals. A SMART pass filter and two tachyarrhythmia zones were programed. ResultsThe most frequent underlying heart disease was Brugada/J wave syndrome (n = 7). During a median follow-up period of 1188 days, an OS was observed in six patients (28.6%). The QRS amplitude in synthesized V7 lead (synV7) was significantly lower in the OS group than in the non-OS group (0.59 +/- 0.17 vs. 0.91 +/- 0.35 mV, p = 0.019). The optimal cutoff value of synV7 QRS amplitude was 0.61 mV, with a sensitivity of 80.0% and a specificity of 83.7% for predicting an OS. Univariate logistic analysis showed that a synV7 QRS amplitude of <0.61 mV was only associated with an OS (odd ratio, 20.0; 95% confidence interval, 1.66-241.72; p = 0.018). ConclusionsIn patients with S-ICDs, an OS was not a rare complication during long-term follow-up. A low synV7 QRS amplitude was associated with a high OS incidence.
引用
收藏
页码:1565 / 1573
页数:9
相关论文
共 50 条
  • [41] Use of Implantable Cardioverter-Defibrillators Among Medicare Patients
    Forman, Daniel E.
    Maurer, Mathew S.
    Rich, Michael W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (17): : 1873 - 1874
  • [42] SUDDEN-DEATH IN PATIENTS WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
    LI, H
    AXTELL, K
    BIEHL, M
    DESHPANDE, SJ
    DHALA, A
    BLANCK, Z
    SRA, J
    JAZAYERI, MR
    AKHTAR, M
    CIRCULATION, 1995, 92 (08) : 3770 - 3770
  • [43] IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS IN PATIENTS WITH LEFT VENTRICULAR NONCOMPACTION
    Sousa, O.
    Dias Ferreira, N.
    Pereira, E.
    Adao, L.
    Oliveira, M.
    Goncalves, H.
    Primo, J.
    Ribeiro, J.
    Fonseca, C.
    Gama, V.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2011, 22 : S155 - S155
  • [44] Adding AI to the Toolkit for Patients With Implantable Cardioverter-Defibrillators
    Ramireddy, Archana
    Braunstein, Eric D.
    Chugh, Sumeet S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (01) : 56 - 57
  • [45] Effect of sensing system on the incidence of myopotential oversensing during bradycardia pacing in implantable cardioverter-defibrillators
    Mann, DE
    Otto, L
    Kelly, PA
    Reiter, MJ
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (11): : 1380 - +
  • [46] System survival of nontransvenous implantable cardioverter-defibrillators compared to transvenous implantable cardioverter-defibrillators in pediatric and congenital heart disease patients
    Radbill, Andrew E.
    Triedman, John K.
    Berul, Charles I.
    Fynn-Thompson, Francis
    Atallah, Joseph
    Alexander, Mark E.
    Walsh, Edward P.
    Cecchin, Frank
    HEART RHYTHM, 2010, 7 (02) : 193 - 198
  • [47] Perioperative management of patients with pacemakers and implantable cardioverter-defibrillators
    Hollenbach, E.
    ANAESTHESIST, 2009, 58 (05): : 451 - 452
  • [48] Shocks as predictors of survival in patients with implantable cardioverter-defibrillators
    Pacifico, A
    Ferlic, LL
    Cedillo-Salazar, FR
    Nasir, N
    Doyle, TK
    Henry, PD
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (01) : 204 - 210
  • [49] Implantable cardioverter-defibrillators in patients with left ventricular noncompaction
    Kobza, Richard
    Jenni, Rolf
    Erne, Paul
    Oechslin, Erwin
    Duru, Firat
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2008, 31 (04): : 461 - 467
  • [50] Benefits of cardiac rehabilitation in patients with implantable cardioverter-defibrillators
    Davids, JS
    McPherson, CA
    Earley, C
    Batsford, WP
    Grubman, E
    Lampert, R
    CIRCULATION, 2003, 108 (17) : 740 - 740